Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Dry Powder Inhalers - Key Annual Conference for Pharmaceutical & Medical Device Professionals in the DPI Market (London, United Kingdom - June 24-25, 2020) - ResearchAndMarkets.com

January 31, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Jan 31, 2020--

The “Dry Powder Inhalers - Key Annual Conference for Pharmaceutical and Medical Device Professionals in the DPI Market” conference has been added to ResearchAndMarkets.com’s offering.

The second generation of DPIs have become either established on the market or are a significant way along the approval process. These have been a great success story in improving inhaled drug delivery. However, we now have to tackle the technical and regulatory issues with generic’ inhalers and their approval.

The development of triple therapies is well underway and these bring about their own challenges of formulation and bioequivalence.

Amazingly, new DPIs are still being created, with some moving into development programmes. One of the areas where much study and recent guidance has been applied is in considering the patient use, compliance and human factors associated with DPIs. These linked topics are creating a whole new area that requires better understanding during product development and associated studies.

The Dry Powder Inhalers conference will address many of the issues around generic inhalers, provide case studies of bioequivalence testing, focus on the difficult formulation challenges and the strategies used so that they may be overcome, and discuss in-depth patient and human factor issues when developing a DPI to gain regulatory approval.

Conference programme to include:


Programme Day One

Current and future challenges for DPI formulations

Novel DPI delivery platforms

Design and characterisation of breath actuation mechanisms (BAMs)

Methods for the determination of delivered-dose uniformity and aerodynamic particle size distributions of DPIs

Sampling and analysis of inhalation devices in accordance with ISO 18562

Development of a new moisture-resistant DPI which performs well irrespective of orientation

How can the physicochemical properties of DPIs and their stability impact product performance? A process and delivery perspective

Spray drying of nanopharmaceuticals into microsphere formulations

Programme Day Two

INFORM 2020: new analytical insights into dry powder formulations for inhalation

Dry powder formulations: from low dosage API delivery to biopharmaceuticals

Inhalation products, transitioning from less to more regulated markets, can it be that difficult?

Formal product characterization studies required for DPI’s

Overcoming the need for comparative clinical endpoint bioequivalence studies in a 505(j) ANDA weight of evidence approach for orally inhaled products

Dr Rob Price

The 1nhaler and its two jobs

Opportunities and challenges in the design of a high-performance unit-dose DPI

For more information about this conference visit https://www.researchandmarkets.com/r/dhp6tg

View source version on businesswire.com:https://www.businesswire.com/news/home/20200131005179/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 01/31/2020 05:09 AM/DISC: 01/31/2020 05:09 AM